HSP90 inhibitor and preparation method and use thereof

US9630925B2 · kind B2 · utility

Assignee

• JINAN UNIVERSITY · CN

Inventors

• Yifei Wang · Pomona, US
• Guowen Xing · 流花街道, CN
• Huaiqiang Ju · 流花街道, CN
• Wenhui Lin · Xiamen, CN
• Chuiwen Qian · 流花街道, CN
• Min Xia · Longbeilingcun, CN
• Xiaoping Zhou · Huzhou City, CN
• Meiying Zhang · 流花街道, CN

Key dates

• Filing date: Feb 16, 2011
• Grant date: Apr 25, 2017
• Expiry date: Sep 12, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are an Hsp90 inhibitor and a preparation method and use thereof. The Hsp90 inhibitor is 2-(4-(3-acetylcarnitineacyloxy)cyclohexylamino)-4-(1-(3,6,6-trimethyl-4-oxy-4,5,6,7-tetrahydroindazole))benzamide. The Hsp90 inhibitor has good water solubility and high bioavailability, and can effectively inhibit the proliferation of cancer cells, such as leukemia, cervical cancer, breast cancer, human laryngeal epithelial carcinoma, or malignant melanoma cells. It can also effectively inhibit the activity of herpes simplex virus. The maximal non-toxic concentration of the Hsp90 inhibitor on normal cells is a high, and the Hsp90 inhibitor only has specific inhibition effect on cancer cells.